Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
85.55 CHF | +3.63% | +4.58% | +16.00% |
Apr. 23 | DOCMORRIS : Deutsche Bank remains its Buy rating | ZD |
Apr. 19 | DOCMORRIS : Hauck & Aufhauser gives a Buy rating | ZD |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is in debt and has limited leeway for investment
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+16.00% | 1.1B | B- | ||
-32.21% | 15.27B | B- | ||
-31.97% | 10.84B | B | ||
-30.42% | 6.06B | B | ||
+8.14% | 6.04B | C | ||
-11.41% | 5.86B | C+ | ||
-1.17% | 4.71B | D- | ||
+52.19% | 4.29B | - | C | |
-14.86% | 3.33B | C- | ||
-6.93% | 3.01B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ROSE Stock
- Ratings DocMorris AG